GOLDMAN SACHS GROUP INC - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$2,328,244
-34.0%
269,785
-20.8%
0.00%
-100.0%
Q2 2023$3,525,200
-3.4%
340,599
+1.2%
0.00%0.0%
Q1 2023$3,650,233
-17.8%
336,427
-15.0%
0.00%0.0%
Q4 2022$4,442,929
-34.9%
395,983
-41.1%
0.00%0.0%
Q3 2022$6,822,000
+29.2%
672,859
+15.4%
0.00%0.0%
Q2 2022$5,282,000
-43.4%
583,029
-40.3%
0.00%
-50.0%
Q1 2022$9,335,000
+145.7%
976,373
+184.0%
0.00%
+100.0%
Q4 2021$3,799,000
+68.7%
343,791
+13.0%
0.00%
Q3 2021$2,252,000
-46.1%
304,257
+5.7%
0.00%
-100.0%
Q2 2021$4,179,000
-27.2%
287,759
+2.4%
0.00%0.0%
Q1 2021$5,737,000
-7.6%
281,120
-19.6%
0.00%
-50.0%
Q4 2020$6,210,000
+33.3%
349,509
+10.9%
0.00%
+100.0%
Q3 2020$4,660,000
-33.5%
315,165
-5.6%
0.00%
-50.0%
Q2 2020$7,010,000
+78.2%
333,945
+96.2%
0.00%
+100.0%
Q1 2020$3,934,000
+30.3%
170,210
+45.9%
0.00%0.0%
Q4 2019$3,020,000
+31.0%
116,648
-1.4%
0.00%0.0%
Q3 2019$2,305,000
-42.4%
118,329
-51.7%
0.00%0.0%
Q2 2019$4,005,000
-33.6%
245,218
-7.8%
0.00%
-50.0%
Q1 2019$6,028,000
+0.3%
265,889
+13.2%
0.00%0.0%
Q4 2018$6,009,000
-16.1%
234,818
+7.1%
0.00%0.0%
Q3 2018$7,166,000
+42.0%
219,343
-1.4%
0.00%
+100.0%
Q2 2018$5,047,000
-55.7%
222,525
-52.7%
0.00%
-66.7%
Q1 2018$11,403,000
+106.9%
470,217
+137.9%
0.00%
+200.0%
Q4 2017$5,512,000
-37.3%
197,618
-23.0%
0.00%
-50.0%
Q3 2017$8,793,000
-7.7%
256,808
+7.4%
0.00%0.0%
Q2 2017$9,528,000
+1.0%
239,176
-6.6%
0.00%
-33.3%
Q1 2017$9,430,000
+409.5%
256,110
+341.2%
0.00%
+200.0%
Q4 2016$1,851,000
+94.0%
58,048
+120.6%
0.00%
Q3 2016$954,000
+165.0%
26,312
+65.7%
0.00%
Q2 2016$360,000
+31.9%
15,882
+9.2%
0.00%
Q1 2016$273,000
-11.7%
14,547
-22.8%
0.00%
Q4 2015$309,000
+87.3%
18,835
+25.3%
0.00%
Q3 2015$165,000
-29.5%
15,030
+104.6%
0.00%
Q2 2014$234,0007,3460.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,012,226$60,515,5108.59%
Irenic Capital Management LP 2,760,948$23,826,9816.76%
Newtyn Management, LLC 1,841,560$15,892,6633.92%
Weiss Asset Management LP 7,457,060$64,354,4283.81%
Park West Asset Management LLC 1,983,251$17,115,4561.57%
Baupost Group 7,419,226$64,0281.23%
Oasis Management Co Ltd. 953,254$8,226,5820.36%
Chescapmanager LLC 287,333$2,479,6840.32%
GSA CAPITAL PARTNERS LLP 325,985$2,8130.24%
Virtus ETF Advisers LLC 29,232$252,2720.15%
View complete list of THERAVANCE BIOPHARMA INC shareholders